Flexion Therapeutics FLXN 深 沪
等待开盘 10-16 09:30:00 美东时间
25.63
+0.070
+0.27%
华盛通- 最 高25.655
- 今 开25.6473
- 成交量 1860股
- 最 低 25.59
- 昨 收 25.56
- 总市值 3280.64万
- 52周最高 25.94
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 4.1542
- 委 比 0.00%
- 总股本 128.00万
- 历史最高 32.1042
- 量 比 1.45
- 振 幅 0.25%
- 历史最低 4.1542
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Lexicon Pharmaceuticals is presenting clinical data on pilavapadin, an investigational AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP), at three medical meetings. The first presentation will be at NeuroDiab on September 13, 2025, followed by EASD on September 17, 2025, and Arrowhead’s Pain Summit on October 13, 2025. Rodica Pop-Busui, M.D., Ph.D., will present at the first two meetings, while Suma Gopinathan, Ph.D., will present th...
09-11 12:30
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
<p>Lexicon Pharmaceuticals submitted additional clinical data to the FDA from third-party funded studies to address concerns raised in the December 2024 complete response letter regarding Zynquista's potential risks. The data aims to support the resubmission of the New Drug Application for Zynquista as a treatment for adults with type 1 diabetes. FDA feedback is expected by the end of September. The company acknowledges strong patient support for...
09-08 12:30
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
<p>Lexicon Pharmaceuticals will present new data on pilavapadin, an AAK1 inhibitor, showing its effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain in Berlin. The findings suggest the potential of pilavapadin for treating additional neuropathic pain conditions beyond diabetic peripheral neuropathic pa...
09-04 12:30
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Lexicon Pharmaceuticals, Inc. announced that its management will participate in fireside chats at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright Global Investment Conference on September 8 at 3:00 p.m. ET. The live events and replays can be accessed via the Company’s website. Lexicon, a biopharmaceutical company, focuses on pioneering medicines through its Genome5000 program, targeting disease...
08-27 12:30
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals reported second quarter 2025 financial results, highlighting increased revenues due to licensing agreements, particularly with Novo Nordisk for LX9851. Key milestones include partnership discussions for pilavapadin progressing, completion of IND-enabling studies for LX9851 expected by 2025, and enrollment on track for the SONATA Phase 3 study in HCM. Additionally, Lexicon remains focused on advancing sotagliflozin in heart...
08-06 11:30
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals announced they will release their second quarter 2025 financial results on August 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET. The webcast and archived version will be available on their website.
07-23 12:00
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Lexicon announced data from a study on diabetic peripheral neuropathic pain (DPNP) patients despite standard treatment, to be presented at the ASPN 2025 meeting. DPNP, a debilitating complication of diabetes affecting millions, often impacts daily life. Lexicon’s investigational drug, pilavapadin, a novel non-opioid treatment targeting AAK1, showed promising results in reducing DNP pain in Phase 2a trials. The company aims to raise awareness of D...
07-18 12:00
Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense
Horizon introduces 2 new ETFs for financial advisors - BNDY and FLXN - to help manage risk and enhance returns in complex markets.
07-08 04:05
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon Pharmaceuticals announced that a post-hoc analysis of data from clinical trials showed that adding sotagliflozin to optimized insulin therapy significantly reduced hypoglycemic events, particularly in individuals with type 1 diabetes (T1D) experiencing blood glucose levels ≤55 mg/dL. The study, presented at the American Diabetes Association's 85th Scientific Sessions, evaluated the impact of kidney function on hypoglycemia risk using esti...
06-23 12:00
